Marker Therapeutics (MRKR) Net Income towards Common Stockholders (2010 - 2026)
Marker Therapeutics (MRKR) reported Net Income towards Common Stockholders of -$3.9 million for Q1 2026, up 17.84% year-over-year from -$3.3 million in Q1 2025, and down 145.73% quarter-over-quarter from $8.6 million in Q4 2025.
Marker Therapeutics (MRKR) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$3.9 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$3.9 million, up 17.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 65.38% YoY), and the FY2025 annual result was -$12.2 million, down 13.35% from the prior year.
- Net Income towards Common Stockholders slipped to -$3.9 million in Q1 2026 per MRKR's latest filing, from $8.6 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $8.6 million in Q4 2025 and troughed at -$9.8 million in Q1 2022.
- A 5-year average of -$1.1 million and a median of -$2.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 8183.41% in 2024 and fell as far as 222.16% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$813062.0 in 2022, then surged by 92.26% to -$62939.0 in 2023, then jumped by 8183.41% to $5.1 million in 2024, then surged by 69.32% to $8.6 million in 2025, then tumbled by 145.73% to -$3.9 million in 2026.
- Business Quant data shows MRKR's Net Income towards Common Stockholders at -$3.9 million in Q1 2026, $8.6 million in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | -3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.94 Mn |
| Dec 31, 2025 | 8.61 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -4.13 Mn |
| Mar 31, 2025 | -4.80 Mn |
| Dec 31, 2024 | 5.09 Mn |
| Sep 30, 2024 | -2.31 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Mar 31, 2024 | -2.39 Mn |
| Dec 31, 2023 | -62,939.00 |
| Jun 30, 2023 | 6.61 Mn |
| Mar 31, 2023 | -742,751.00 |
| Dec 31, 2022 | -813,062.00 |
| Sep 30, 2022 | -1.19 Mn |
| Jun 30, 2022 | -4.01 Mn |
| Mar 31, 2022 | -9.79 Mn |
| Dec 31, 2021 | -9.76 Mn |
| Sep 30, 2021 | -10.02 Mn |
| Jun 30, 2021 | -10.91 Mn |
| Mar 31, 2021 | -8.78 Mn |